Results 61 to 70 of about 27,184 (256)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide

Frontiers in Pharmacology, 2020
Background: HIV pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine is effective when taken daily. Previously, we developed a urine assay capable of detecting the prodrug tenofovir (TFV) in patients taking tenofovir disoproxil fumarate (TDF ...
Linden Lalley-Chareczko, Emily Hiserodt, Ganesh Moorthy, Athena Zuppa, Karam Mounzer, Helen Koenig, Helen Koenig   +6 more
doaj   +1 more source

Highlights from the 24th conference on retroviruses and opportunistic infections, 13-16 February 2017, Seattle, Washington, USA [PDF]

, 2017
From the 13th to 16th February 2017, researchers from around the world convened for the 24th annual Conference on Retroviruses and Opportunistic Infections (CROI) at the Washington State Convention Center in Seattle, Washington.
Bhagani, Sanjay, Colby, Donn J, Crowell, Trevor A, Gathogo, Esther N, Hill, Andrew, Hsu, Denise, Kinloch, Sabine, Lyall, Hermione, Malatinková, Eva, Polyak, Christina, Psomas, Christina, Trypsteen, Wim, Vandekerckhove, Linos   +12 more
core   +5 more sources

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, EarlyView.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Discordant Liver Fibrosis Predictors in Virologically Suppressed People Living with HIV without Hepatitis Virus Infection

Diagnostics, 2021
Severe liver fibrosis (LF) is associated with poor long-term liver-related outcomes in people living with HIV (PLWH). The study aimed to explore the prevalence and predictors of LF and the concordance between different non-invasive methods for the ...
Barbara Rossetti, Valentina Borgo, Arianna Emiliozzi, Marta Colaneri, Giacomo Zanelli, Miriana d’Alessandro, Davide Motta, Laura Maiocchi, Francesca Montagnani, Maria Cristina Moioli, Chiara Baiguera, Margherita Sambo, Teresa Chiara Pieri, Pietro Valsecchi, Raffaele Bruno, Massimo Puoti, Massimiliano Fabbiani   +16 more
doaj   +1 more source

Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. [PDF]

, 2016
There have been dramatic advancements in the treatment of chronic hepatitis C (HCV) infection. This is largely due to the approval of several direct-acting antiviral agents (DAAs) from a variety of medication classes with novel mechanisms of action ...
Bidell, Monique R, Faragon, John, McLaughlin, Milena, Morse, Caroline, Patel, Nimish   +4 more
core   +2 more sources

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

HIV Medicine, EarlyView.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Mark Zuckerman, Sally Hawkins, Kate Childs, Frank A. Post   +6 more
wiley   +1 more source

Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials

International Journal of Infectious Diseases, 2020
Background: Tenofovir disoproxil fumarate (TDF) can cause renal and bone toxicity, which is associated with high plasma tenofovir concentrations in antiretroviral treatment of HIV-1 infected patients.
Xingbao Tao, Yanqiu Lu, Yihong Zhou, Lvlang Zhang, Yaokai Chen   +4 more
doaj   +1 more source

A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection [PDF]

, 2014
A number of antiviral agents used against Human Immunodeficiency Virus (HIV) infection and hepatitis B virus (HBV) mono or co-infection have been associated with real nephrotoxicity (including tenofovir disoproxil fumarate (TDF), atazanavir, indinavir ...
Abbas, R., Baer, R., Boyd, M., Gracey, D., Holt, S., Irish, A., Levy, M., Mudge, D., Sevastos, J., Walker, R.   +9 more
core   +3 more sources

A United States HIV provider survey of antiretroviral therapy management in people living with HIV with co-occurring conditions

AIDS Research and Therapy
Introduction Simplified HIV treatment guidelines favor integrase strand transfer inhibitors (INSTIs). However, non-infectious comorbidities and co-occurring conditions (i.e.
Sonya Krishnan, Marina B. Martinez Rivera, Christopher K. Lippincott, Maunank Shah   +3 more
doaj   +1 more source

Health care providers' decision-making and early adoption of tenofovir alafenamide for HIV preexposure prophylaxis: An inductive qualitative study.

PLoS ONE
BackgroundOver the past several years, there have been several changes affecting the available options for oral HIV preexposure prophylaxis, including approvals for tenofovir alafenamide with emtricitabine in 2019 and a generic formulation of tenofovir ...
Elisabeth Merchant, Patricia Solleveld, Kevin Gibas, Douglas Krakower   +3 more
doaj   +1 more source